Literature DB >> 30762

Clinical pharmacokinetics of lorazepam: a review.

A A Kyriakopoulos, D J Greenblatt, R I Shader.   

Abstract

The clinical pharmacokinetics of lorazepam, a 3-hydroxy, 1,4-benzodiazepine, indicate that it is rapidly and readily absorbed, reaching peak concentrations in the blood proportional to the dose approximately 2 hours after oral administration. Blood levels decline thereafter, with an elimination half-life of about 12 hrs. Conjugation with glucuronic acid to form inactive lorazepam glucuronide is the major metabolic pathway. Seventy (70) to 75% of the administered dose is excreted as the glucuronide conjugate in the urine. On multiple-dose regimens, steady state blood levels directly proportional to the daily dose occur within 2--3 days and are maintained after several months of continuous treatment. The active drug and the glucuronide conjugate are completely eliminated from the blood within 1 week following the last dose.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 30762

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  17 in total

Review 1.  Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: a comparative review.

Authors:  Hervé Allain; Danièle Bentué-Ferrer; Elisabeth Polard; Yvette Akwa; Alain Patat
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

2.  GABAA receptor subtype specific enhancement of inhibition in human motor cortex.

Authors:  Vincenzo Di Lazzaro; Fabio Pilato; Michele Dileone; Federico Ranieri; Valerio Ricci; Paolo Profice; Pietro Bria; Pietro A Tonali; Ulf Ziemann
Journal:  J Physiol       Date:  2006-06-29       Impact factor: 5.182

3.  Effects of lorazepam and baclofen on short- and long-latency afferent inhibition.

Authors:  Claudia V Turco; Jenin El-Sayes; Mitchell B Locke; Robert Chen; Steven Baker; Aimee J Nelson
Journal:  J Physiol       Date:  2018-10-03       Impact factor: 5.182

4.  Lorazepam dose-dependently decreases risk-taking related activation in limbic areas.

Authors:  Estibaliz Arce; Daniel A Miller; Justin S Feinstein; Murray B Stein; Martin P Paulus
Journal:  Psychopharmacology (Berl)       Date:  2006-10-03       Impact factor: 4.530

5.  The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers.

Authors:  Manami Oda; Tsutomu Kotegawa; Kimiko Tsutsumi; Yasukiyo Ohtani; Keiji Kuwatani; Shigeyuki Nakano
Journal:  Eur J Clin Pharmacol       Date:  2003-09-27       Impact factor: 2.953

Review 6.  Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations.

Authors:  Catherine C Crone; Geoffrey M Gabriel
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of oxazepam and lorazepam.

Authors:  D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1981 Mar-Apr       Impact factor: 6.447

8.  Automated Detection of Benzodiazepine Dosage in ICU Patients through a Computational Analysis of Electrocardiographic Data.

Authors:  Maxwell T Spadafore; Zeeshan Syed; Ilan S Rubinfeld
Journal:  AMIA Annu Symp Proc       Date:  2015-11-05

9.  Effects of chlorpromazine and lorazepam on explicit memory, repetition priming and cognitive skill learning in healthy volunteers.

Authors:  J M Danion; S Peretti; D Grangé; M Bilik; J L Imbs; L Singer
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

10.  Differing effects of intracortical circuits on plasticity.

Authors:  J T H Teo; C Terranova; O Swayne; R J Greenwood; J C Rothwell
Journal:  Exp Brain Res       Date:  2008-12-02       Impact factor: 1.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.